Patent ID: 7829120

Claim:
A sustained release pharmaceutical composition for once a day oral administration comprising about 20% to about 50% by weight of trazodone or a derivative thereof, about 20% to about 50% by weight of cross-linked high amylose starch, about 10% to about 25% by weight of hydroxypropylmethylcellulose, about 0% to about 5% by weight of cetylpyridinium chloride, about 0% to about 20% by weight of alginic acid, about 1% to about 5% by weight of sodium stearyl fumarate, and up to about 1% by weight of colloidal silicon dioxide, wherein the composition, when administered orally to a mammal, releases the trazodone or the derivative thereof so as to maintain a substantially constant effective plasma concentration between about 50 ng/mL and about 3000 ng/mL from at least about one hour to at least about 24 hours after initial administration.